Clinical trials: Pulmonary Hypertension
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary, Ventricular Dysfunction, Left
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
- Trial name
- LEPHT (NCT01065454)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 83 sites in United States, Australia and 16 more
- Volunteers
- 202 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year.
- Trial name
- REPAIR (NCT02310672)
- Testing
- Macitentan
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 89 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies
Left Ventricular Dysfunction, Right Ventricular Dysfunction
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
This study is to collect data and learn more about the Vscan Ultrasound Imaging System. It is an "observational" study with no additional procedures or intervention prescribed other than using the Vscan along with a routine…
- Conditions
- Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases
- Trial name
- NCT01076296
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- GE Healthcare
Pulmonary Arterial Hypertension
Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
The purpose of this clinical study is to assess the safety of PLX-PAD to treat pulmonary arterial hypertension (PAH). PLX-PAD is a cell-based product made of allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs), derived from…
- Trial name
- NCT01795950
- Testing
- PLX-PAD
- Where
- 2 sites in Australia
- Volunteers
- 6 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease…
- Trial name
- NCT07441278
- Testing
- NS-863 Low Dose, NS-863 High Dose
- Where
- 2 sites in United States, Japan
- Volunteers
- 177 people
- Sponsor
- NS Pharma, Inc.
Pulmonary Arterial Hypertension
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with…
- Trial name
- TOMORROW (NCT02932410)
- Testing
- Macitentan, Standard-of-care
- Where
- 85 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
The purpose of this study is to compare the pharmacokinetics of two Traclear 62.5 mg tablets and one HGP1206 125 mg tablet in healthy male volunteers.
- Trial name
- NCT01864863
- Testing
- HGP1206, Traclear
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension, Pulmonary
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension
- Trial name
- NCT00414687
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Volunteers
- 63 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing…
- Trial name
- OrPHeUS (NCT03197688)
- Testing
- Notapplicable
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 2,200 people
- Sponsor
- Actelion
Primary Hypertension
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
- Trial name
- NCT00882947
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo.
- Trial name
- UK 92480 (NCT00878943)
- Testing
- Sildenafil citrate
- Where
- 5 sites in India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
- Trial name
- NCT03464864
- Testing
- Treprostinil Inhalation Powder
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Trial name
- NCT06581159
- Testing
- HS135
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Arterial Hypertension
A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study. Primary objectives: To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian and Spanish…
- Trial name
- ORCHESTRA (NCT02081690)
- Testing
- Macitentan
- Where
- 39 sites in France, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
A multinational, multicenter, double-blind, randomized, placebo-controlled, Phase III study to assess the efficacy and safety of BPS 314d-MR in subjects with pulmonary arterial hypertension currently receiving treatment with an…
- Trial name
- NCT01458236
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Sponsor
- Lung Biotechnology PBC
Hypertension, Pulmonary
Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
This study is collecting post-marketing information on the safety and effectiveness of Ventavis under the routine clinical practice for patients with PAH
- Trial name
- NCT02825160
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- Japan
- Volunteers
- 282 people
- Sponsor
- Bayer